Joanna Richey

Learn More
Despite clinical approval of erlotinib, most advanced lung cancer patients are primary non-responders. Initial responders invariably develop secondary resistance, which can be accounted for by T790M-EGFR mutation in half of the relapses. We show that MET is highly expressed in lung cancer, often concomitantly with epidermal growth factor receptor (EGFR),(More)
won a prestigious national award for performance measure reporting from the Association of Government Accountants (AGA)for the past two consecutive years (2003 and 2004). Certificate of achievement presented to King County Department of Natural Resources and Parks for your outstanding efforts in producing a high quality service efforts and accomplishments(More)
  • 1